These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 36827406)
1. Differences in clinical significance of bronchodilator responses measured by forced expiratory volume in 1 second and forced vital capacity. Choi JY; Kim SK; Lee JH; Jung KS; Yoo KH; Hwang KE; Lee JD; Kim YI; Yoon HK; Um SJ PLoS One; 2023; 18(2):e0282256. PubMed ID: 36827406 [TBL] [Abstract][Full Text] [Related]
2. Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. Fortis S; Comellas A; Make BJ; Hersh CP; Bodduluri S; Georgopoulos D; Kim V; Criner GJ; Dransfield MT; Bhatt SP; Ann Am Thorac Soc; 2019 Jul; 16(7):826-835. PubMed ID: 30908927 [No Abstract] [Full Text] [Related]
3. A New Bronchodilator Response Grading Strategy Identifies Distinct Patient Populations. Hansen JE; Dilektasli AG; Porszasz J; Stringer WW; Pak Y; Rossiter HB; Casaburi R Ann Am Thorac Soc; 2019 Dec; 16(12):1504-1517. PubMed ID: 31404502 [No Abstract] [Full Text] [Related]
4. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD. Fortis S; Quibrera PM; Comellas AP; Bhatt SP; Tashkin DP; Hoffman EA; Criner GJ; Han MK; Barr RG; Arjomandi M; Dransfield MB; Peters SP; Dolezal BA; Kim V; Putcha N; Rennard SI; Paine R; Kanner RE; Curtis JL; Bowler RP; Martinez FJ; Hansel NN; Krishnan JA; Woodruff PG; Barjaktarevic IZ; Couper D; Anderson WH; Cooper CB; Chest; 2023 Mar; 163(3):502-514. PubMed ID: 36395858 [TBL] [Abstract][Full Text] [Related]
5. Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness. Mümmler C; Suhling H; Walter J; Kneidinger N; Buhl R; Kayser MZ; Drick N; Behr J; Welte T; Korn S; Milger K J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3174-3183. PubMed ID: 35870725 [TBL] [Abstract][Full Text] [Related]
6. Clinical characterization and outcomes of impulse oscillometry-defined bronchodilator response: an ECOPD cohort-based study. Lu L; Wu F; Peng J; Wu X; Hou X; Zheng Y; Yang H; Deng Z; Dai C; Zhao N; Zhou K; Wan Q; Tang G; Cui J; Yu S; Luo X; Yang C; Chen S; Ran P; Zhou Y Respir Res; 2024 Mar; 25(1):149. PubMed ID: 38555433 [TBL] [Abstract][Full Text] [Related]
7. Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease. Li Y; Lin J; Wang Z; Wang Z; Tan L; Liu S; Huang J; Gao Y; Zheng J Int J Chron Obstruct Pulmon Dis; 2022; 17():2623-2633. PubMed ID: 36274994 [TBL] [Abstract][Full Text] [Related]
8. The paradoxical response to short-acting bronchodilator administration in patients with chronic obstructive pulmonary disease. Shin HJ; Kim TO; Kim YI; Kim SH; Kim HK; Kim YH; Byun MK; Jung KS; Yoo KH; Lee JS; Lim SC; J Thorac Dis; 2021 Feb; 13(2):511-520. PubMed ID: 33717524 [TBL] [Abstract][Full Text] [Related]
9. Lung Function and the Risk of Exacerbation in the β-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Trial. Parekh TM; Helgeson ES; Connett J; Voelker H; Ling SX; Lazarus SC; Bhatt SP; MacDonald DM; Mkorombindo T; Kunisaki KM; Fortis S; Kaminsky D; Dransfield MT Ann Am Thorac Soc; 2022 Oct; 19(10):1642-1649. PubMed ID: 35363600 [No Abstract] [Full Text] [Related]
10. Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis. Barjaktarevic IZ; Buhr RG; Wang X; Hu S; Couper D; Anderson W; Kanner RE; Paine Iii R; Bhatt SP; Bhakta NR; Arjomandi M; Kaner RJ; Pirozzi CS; Curtis JL; O'Neal WK; Woodruff PG; Han MK; Martinez FJ; Hansel N; Wells JM; Ortega VE; Hoffman EA; Doerschuk CM; Kim V; Dransfield MT; Drummond MB; Bowler R; Criner G; Christenson SA; Ronish B; Peters SP; Krishnan JA; Tashkin DP; Cooper CB; Int J Chron Obstruct Pulmon Dis; 2019; 14():2927-2938. PubMed ID: 31908441 [TBL] [Abstract][Full Text] [Related]
11. Bronchodilator Response in FVC Is Larger and More Relevant Than in FEV Quanjer PH; Ruppel GL; Langhammer A; Krishna A; Mertens F; Johannessen A; Menezes AMB; Wehrmeister FC; Perez-Padilla R; Swanney MP; Tan WC; Bourbeau J Chest; 2017 May; 151(5):1088-1098. PubMed ID: 28040521 [TBL] [Abstract][Full Text] [Related]
12. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Reid DW; Soltani A; Johns DP; Bish R; Williams TJ; Burns GP; Walters EH Intern Med J; 2003 Dec; 33(12):572-7. PubMed ID: 14656230 [TBL] [Abstract][Full Text] [Related]
13. The prevalence of bronchodilator responsiveness of the small airway (using mid-maximal expiratory flow) in COPD - a retrospective study. Alobaidi NY; Almeshari MA; Stockley JA; Stockley RA; Sapey E BMC Pulm Med; 2022 Dec; 22(1):493. PubMed ID: 36585669 [TBL] [Abstract][Full Text] [Related]
14. Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients? Kim J; Kim WJ; Lee CH; Lee SH; Lee MG; Shin KC; Yoo KH; Lee JH; Lim SY; Na JO; Hwang HG; Hong Y; Lim MN; Yoo CG; Jung KS; Lee SD Respir Res; 2017 May; 18(1):107. PubMed ID: 28558829 [TBL] [Abstract][Full Text] [Related]
15. Effect of a single exacerbation on decline in lung function in COPD. Halpin DMG; Decramer M; Celli BR; Mueller A; Metzdorf N; Tashkin DP Respir Med; 2017 Jul; 128():85-91. PubMed ID: 28610675 [TBL] [Abstract][Full Text] [Related]
16. Bronchodilator Reversibility in the GAN Severe Asthma Cohort. Milger K; Skowasch D; Hamelmann E; Mümmler C; Idzko M; Gappa M; Jandl M; Körner-Rettberg C; Ehmann R; Schmidt O; Taube C; Holtdirk A; Timmermann H; Buhl R; Korn S J Investig Allergol Clin Immunol; 2023 Dec; 33(6):446-456. PubMed ID: 36000830 [TBL] [Abstract][Full Text] [Related]
17. Ratio of FEV Fortis S; Comellas AP; Bhatt SP; Hoffman EA; Han MK; Bhakta NR; Paine R; Ronish B; Kanner RE; Dransfield M; Hoesterey D; Buhr RG; Barr RG; Dolezal B; Ortega VE; Drummond MB; Arjomandi M; Kaner RJ; Kim V; Curtis JL; Bowler RP; Martinez F; Labaki WW; Cooper CB; O'Neal WK; Criner G; Hansel NN; Krishnan JA; Woodruff P; Couper D; Tashkin D; Barjaktarevic I Chest; 2021 Jul; 160(1):94-103. PubMed ID: 33539837 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. Richter DC; Joubert JR; Nell H; Schuurmans MM; Irusen EM Int J Chron Obstruct Pulmon Dis; 2008; 3(4):693-9. PubMed ID: 19281083 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneous burden of lung disease in smokers with borderline airflow obstruction. Pirozzi CS; Gu T; Quibrera PM; Carretta EE; Han MK; Murray S; Cooper CB; Tashkin DP; Kleerup EC; Barjaktarevic I; Hoffman EA; Martinez CH; Christenson SA; Hansel NN; Graham Barr R; Bleecker ER; Ortega VE; Martinez FJ; Kanner RE; Paine R; Respir Res; 2018 Nov; 19(1):223. PubMed ID: 30454050 [TBL] [Abstract][Full Text] [Related]
20. Rate of Forced Expiratory Volume in One Second and Forced Expiratory Volume in One Second/Forced Vital Capacity Decline among Indonesian Patients with Chronic Obstructive Pulmonary Disease after a Year of Treatment. Ariawan WP; Yunus F; Damayanti T; Nurwidya F Int J Appl Basic Med Res; 2019; 9(2):95-99. PubMed ID: 31041172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]